Markers for Chronic Obstructive Pulmonary Disease (COPD)

Imperial College London

Status: Withdrawn

Conditions: Current Smokers; COPD Patients; Healthy Non-smokers

Treatments: Procedure: St Georges Questionnaire; Procedure: Blood test; Procedure: CT Scan; Procedure: Exhaled Breath Condensate; Procedure: Bodypletysmography; Procedure: Induced Sputum; Procedure: Spirometry; Procedure: Exhaled Nitric Oxide and Carbon Monoxide

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00180622

SD-000-068

Details and patient eligibility

About

The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).

Sex: All

Ages: 30 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy non-smokers

• FEV1 >80% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists

Current smokers

• FEV1 no less than 80% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists
• Smoking history of > 10 pack-years

Moderate COPD

• FEV1 40-59% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists
• Smoking history of > 10 pack-years**

Severe COPD

• FEV1 <40% predicted
• FEV1 reversibility of <10% after inhaled (beta2-agonists
• Smoking history of > 10 pack-years

Exclusion criteria

• FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists
• Asthma
• unstable disease (FEV1 <35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.